These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
265 related items for PubMed ID: 12668698
21. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699 [Abstract] [Full Text] [Related]
22. The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Dawson A, Davies JI, Struthers AD. Expert Rev Cardiovasc Ther; 2004 Jan 03; 2(1):29-36. PubMed ID: 15038411 [Abstract] [Full Text] [Related]
23. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Verma A, Solomon SD. Curr Heart Fail Rep; 2007 Dec 03; 4(4):183-9. PubMed ID: 18221614 [Abstract] [Full Text] [Related]
29. Review article: eplerenone: an underused medication? Abuannadi M, O'Keefe JH. J Cardiovasc Pharmacol Ther; 2010 Dec 01; 15(4):318-25. PubMed ID: 20876342 [Abstract] [Full Text] [Related]
30. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668 [Abstract] [Full Text] [Related]
31. Eplerenone in the treatment of chronic heart failure. Krum H, Liew D. Expert Rev Cardiovasc Ther; 2004 May 12; 2(3):315-20. PubMed ID: 15151479 [Abstract] [Full Text] [Related]
32. Aldosterone target organ protection by eplerenone. Rudolph AE, Rocha R, McMahon EG. Mol Cell Endocrinol; 2004 Mar 31; 217(1-2):229-38. PubMed ID: 15134822 [Abstract] [Full Text] [Related]
33. Eplerenone after myocardial infarction? Drug Ther Bull; 2008 Jan 31; 46(1):1-3. PubMed ID: 18171726 [Abstract] [Full Text] [Related]
34. [Is eplerenone nephrotoxic?]. Krämer B. Dtsch Med Wochenschr; 2012 Nov 31; 137(45):2340. PubMed ID: 23070799 [No Abstract] [Full Text] [Related]
36. Aldosterone receptor blockade: a therapy resurrected. Sica DA. Heart Dis; 2003 Nov 31; 5(2):85-8. PubMed ID: 12713674 [No Abstract] [Full Text] [Related]
37. Role of the selective aldosterone receptor blockers in arterial hypertension. Sierra C, Ruilope LM. J Renin Angiotensin Aldosterone Syst; 2004 Mar 31; 5(1):23-5. PubMed ID: 15136969 [Abstract] [Full Text] [Related]
38. Sudden death in patients with myocardial infarction. Pitt B, EPHESUS Investigators. N Engl J Med; 2005 Sep 22; 353(12):1294-7; author reply 1294-7. PubMed ID: 16177257 [No Abstract] [Full Text] [Related]
39. Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION. Teerlink JR, Massie BM, EPHESUS and COMPANION. J Card Fail; 2003 Jun 22; 9(3):158-63. PubMed ID: 12815564 [No Abstract] [Full Text] [Related]
40. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. Keating GM, Plosker GL. Drugs; 2004 Jun 22; 64(23):2689-707. PubMed ID: 15537370 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]